Evidence map›Paper›PMID 29214524›Full record

ArticleJIMD reports2018

Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.

Ahmed Reda, Ann Van Schepdael, Erwin Adams, Prasanta Paul, David Devolder, Mohamed A Elmonem, Koenraad Veys, Ingele Casteels, Lambertus van den Heuvel, Elena Levtchenko

Abstract read
In one paragraph

Article in JIMD reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Ahmed RedaDepartment of Development and Regeneration, Organ System Cluster, Group of Biomedical Sciences, KU Leuven, Leuven, Belgium. ahmed.reda@kuleuven.be.
Ann Van SchepdaelFarmaceutische Analyse, KU Leuven, Leuven, Belgium.
Erwin AdamsFarmaceutische Analyse, KU Leuven, Leuven, Belgium.
Prasanta PaulFarmaceutische Analyse, KU Leuven, Leuven, Belgium.
David DevolderHospital Pharmacy, University Hospitals Leuven, Leuven, Belgium.
Mohamed A ElmonemDepartment of Development and Regeneration, Organ System Cluster, Group of Biomedical Sciences, KU Leuven, Leuven, Belgium.
Koenraad VeysDepartment of Development and Regeneration, Organ System Cluster, Group of Biomedical Sciences, KU Leuven, Leuven, Belgium.
Ingele CasteelsDepartment of Ophthalmology, University Hospitals Leuven, Leuven, Belgium.
Lambertus van den HeuvelDepartment of Development and Regeneration, Organ System Cluster, Group of Biomedical Sciences, KU Leuven, Leuven, Belgium.
Elena LevtchenkoDepartment of Development and Regeneration, Organ System Cluster, Group of Biomedical Sciences, KU Leuven, Leuven, Belgium.
KU Leuven · BERadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystinosis is a hereditary genetic disease that results in the accumulation of cystine crystals in the lysosomes, leading to many clinical manifestations. One of these manifestations is the formation of corneal cystine crystals, which can cause serious ocular complications. The only available drug to treat cystinosis is cysteamine, which breaks cystine and depletes its accumulation in the lysosomes. However, the oral form of cysteamine is not effective in treating corneal manifestations. Thus, ophthalmic solutions of cysteamine are applied. Because the commercial cysteamine eye drops are not available in most countries, hospital pharmacies are responsible for preparing "homemade" drops usually without a control of stability of cysteamine in different storage conditions. Hence, we aimed in this study to investigate the effect of different storage conditions on the stability of a cysteamine ophthalmic compounded solution. Cysteamine ophthalmic solution was prepared in the hospital pharmacy and sterilized using a candle filter. The preparations are then stored either in the freezer at -20°C or in the refrigerator at +4°C for up to 52 weeks. The amount of cysteamine hydrochloride in the preparation at different time points was determined using capillary electrophoresis (CE). Storage of the cysteamine ophthalmic preparations at +4° resulted in significant loss of free cysteamine at all time points, from 1 to 52 weeks of storage, when compared with storage in the freezer (-20°C). We demonstrate that cysteamine 0.5% compounded eye drops are easily oxidized within the first week after storage at +4°C, rendering the preparation less effective. Storage at -20°C is recommended to prevent this process.

Indexed as

CysteamineCystinosisOphthalmic preparation

Identifiers

PMID29214524
PMCPMC6226390
OpenAlexW2774372809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.